Recent research emphasizes the role of hormones that communicate with the hypothalamus through the gut-brain axis, affecting appetite, insulin secretion, and body weight via specific signaling pathways
This is not a prescription
GLP-1 is generated by enteroendocrine cells in the stomach that controls meal-related hyperglycemia by boosting insulin and decreasing glucagon release
Here's what you need to know: Insulin Resistance : GLP-1 drugs improve how the body handles insulin, reducing androgen production and improving ovulation
Monotherapy In the LEAD-3 trial, both doses of liraglutide as monotherapy demonstrated significant improvements in glycemic control in comparison with glimepiride ( Table 19 - 5 )
At 68 weeks (roughly 16 months), the STEP 1 trial showed average weight loss of 14.9% with semaglutide versus 2.4% with placebo